Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Swidnik, Poland Clinical Trials

A listing of Swidnik, Poland clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Safety Tolerability Pharmacokinetics Pharmacodynamics and Immunogenicity of AMG 592 in Participants With Systemic Lupus Erythematosus

To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of AMG 592 in participants with systemic lupus erythematosus (SLE).

Phase

0.0 miles

Learn More »

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

This study is a Phase 1, open-label, dose escalation and cohort expansion study designed to characterize the safety, tolerability, PK, PD, immunogenicity, and preliminary anti-tumor activity of INCMGA00012 administered IV every 2, 3, or 4 weeks in patients with relapsed/refractory, unresectable locally advanced or metastatic solid tumors. In the initial …

Phase

4.26 miles

Learn More »

Study of TSR-042 an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody in Participants With Advanced Solid Tumors

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics …

Phase

6.0 miles

Learn More »

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301 (cosibelimab), a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months of visits with survival follow-up for select cohorts). …

Phase

7.53 miles

Learn More »